Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
Marc K NielsenAndreas W NielsenAgnete O DonskovIb T HansenBerit D NielsenChristoffer MørkEllen M HaugeKresten K KellerPublished in: Seminars in arthritis and rheumatism (2024)
This is the first study indicating that TCZ taper induced longer relapse-free survival than abrupt discontinuation, implying that taper may be favored over discontinuation in patients with GCA.